Page 72 - MemoriaBBN-Eng

RESEARCH GROUPS

ó

á
á

é

Ó

í

PROGRAMME:
Biomaterials and Cell Therapy Research Group

Tissue Engineering

Group Members
Lead Researcher
í
Blanco Fernández, Jerónimo
STAFF MEMBERS
Fernndez Vila, Olaia

Garrido Lpez, Cristina Pilar
Contact:
Guerra Rebollo, Marta
Instituto de Qumica Avanzada de Cataluña.

E.mail: [email protected] ASSOCIATED MEMBERS
http://www.iqac.csic.es/index.php?option=com_ogngrups&view=detall_ Mateo Gonzlez, Francesca

grup&Itemid=95&cid=72&lang=es
Rubio Vidal, Nuria
Thomson Okatsu, Thimothy

CONTRIBUTORS
Aguilar Bohorquez, Elisabeth Main lines of research

Alieva Kraseninnikova, Mara
Meca Corts, scar
• TISSUE ENGINEERING: Study of interactions between cells and biomaterials implan-
ted in live animals for tissue regeneration. We use an analysis platform based in biolu-
minescence and fluorescence procedures, that allows rapid and comparative analysis

of biomaterials to optimize individualized applications.

• TUMOUR CELL THERAPY: Development of optimized cell therapies against brain tumors
and other types of incurable cancers. The therapy strategy is based on the use of stem

cells with tumour homing capacity, that are genetically modified to express a cytotoxic 13
gene (e.g., thymidine kinase) that can transform a harmless pro-drug into a cytotoxic 20
T
agent, inducing localized cell death in the tumour proximity (bystander effect).
R
• INTERACTION BETWEEN TUMOUR AND THERAPEUTIC CELLS: The objective is to un- PO
E
derstand the interactions between therapeutic and tumour cells, that lead to the ele- L R
vated tumour killing effect in our model of bystander therapy. Bioluminescence and A
NU
fluorescence imaging procedures are used to monitor the fate of therapeutic cells and N
tumours.
A
/
• SYSTEMS BIOLOGY AND THERAPEUTIC TARGET IDENTIFICATION OF METASTATIC BN
B
CANCER STEM CELLS In this line of research, we generate and characterize cell R-
models through the manipulation of genes known or suspected to confer metasta- BE
CI
tic cancer stem cell (CSC) properties to tumor cells. The characterizations include
72
phenotypic analysis in vitro and in mouse xenograft models, whole transcriptomic

analysis (microarray and RNAseq), metabolomics, glycolytic flux balance analysis